Condition: MDS · AML, Adult · Anemia · Sponsor: Centre Hospitalier Universitaire de Nice
Patients with refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) in exclusive palliative care frequently receive red blood cell transfusions based on hemoglobin thresholds, despite limited evidence of clinical benefit in this setting. This prospective randomized study compares a standard hemoglobin-based transfusion strategy to a quality-of-life-guided strategy using the EQ-5D-5L questionnaire, with the aim of reducing transfusion burden while maintaining patient safety and quality of life.
This description comes directly from the study's public registry record.
Thomas Cluzeau, Professor · 0492039025 · cluzeau.t@chu-nice.fr
Lydia Cherfaoui · 0492039025 · cherfaoui.l@chu-nice.fr
Always discuss trial participation with your own doctor first.
| CHU de Nice | Nice, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07328191